Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis

Journal of Nephrology

Volumn 29, Issue 3, 2016, Pages 359-365

  Rintala, Jukka M ^a   Savikko, Johanna ^a,b   Rintala, Sini E ^a   Palin, Niina ^a   Koskinen, Petri K ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Epidermal growth factor; Erlotinib; Experimental glomerulonephritis

Indexed keywords

ERLOTINIB; MACROGOL; PARAFORMALDEHYDE; THY 1 ANTIGEN; ALLOANTIBODY; ANTI-THY ANTIBODY; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOLYSIS; EXPERIMENTAL GLOMERULONEPHRITIS; FOLLOW UP; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MACROPHAGE; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; NONHUMAN; PROTEINURIA; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; GLOMERULONEPHRITIS; KIDNEY; PATHOLOGY; WISTAR RAT;

ANIMALS; CREATININE; ERLOTINIB HYDROCHLORIDE; GLOMERULONEPHRITIS; ISOANTIBODIES; KIDNEY; MALE; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84969920394     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-015-0233-x     Document Type: Article

References (23)

1. Levy M, Berger J (1988) Worldwide perspective of IgA nephropathy. Am J Kidney Dis 12(5):340–347
2. Emancipator SN, Lamm ME (1989) IgA nephropathy: overproduction or decreased clearance of immune complexes? Lab Invest 61(4):365–367
3. Couser WG (1993) Mediation of immune glomerular injury. Clin Investig 71(10):808–811
4. Holbro T, Hynes NE (2004) ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44:195–217
5. Wetzker R, Bohmer FD (2003) Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4(8):651–657
6. Watanabe T, Barker TA, Berk BC (2005) Angiotensin II and the endothelium: diverse signals and effects. Hypertension 45(2):163–169
7. Mezzano SA, Ruiz-Ortega M, Egido J (2001) Angiotensin II and renal fibrosis. Hypertension 38(3 Pt 2):635–638
8. Kasselberg AG, Orth DN, Gray ME, Stahlman MT (1985) Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues. J Histochem Cytochem 33(4):315–322
9. Harris RC (1991) Potential physiologic roles for epidermal growth factor in the kidney. Am J Kidney Dis 17(6):627–630
10. Harris RC, Hoover RL, Jacobson HR, Badr KF (1988) Evidence for glomerular actions of epidermal growth factor in the rat. J Clin Invest 82(3):1028–1039
11. Norman J, Badie-Dezfooly B, Nord EP, Kurtz I, Schlosser J, Chaudhari A et al (1987) EGF-induced mitogenesis in proximal tubular cells: potentiation by angiotensin II. Am J Physiol 253(2 Pt 2):F299–F309
12. Okada H, Danoff TM, Kalluri R, Neilson EG (1997) Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 273(4 Pt 2):F563–F574
13. Creely JJ, DiMari SJ, Howe AM, Hyde CP, Haralson MA (1990) Effects of epidermal growth factor on collagen synthesis by an epithelioid cell line derived from normal rat kidney. Am J Pathol 136(6):1247–1257
14. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, Briand P et al (2000) Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest 106(2):225–234
15. Flamant M, Bollee G, Henique C, Tharaux PL (2012) Epidermal growth factor: a new therapeutic target in glomerular disease. Nephrol Dial Transplant 27(4):1297–1304
16. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521–529
17. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966
18. Bollee G, Flamant M, Schordan S, Fligny C, Rumpel E, Milon M et al (2011) Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 17(10):1242–1250
19. Wada Y, Iyoda M, Matsumoto K, Shindo-Hirai Y, Kuno Y, Yamamoto Y et al (2014) Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. PLoS One 9(11):e111728
20. Rintala JM, Savikko J, Palin N, Rintala SE, Koskinen PK, von Willebrand E (2014) Epidermal growth factor inhibition, a novel pathway to prevent chronic allograft injury. Transplantation 98(8):821–827
21. Savikko J, Rintala JM, Rintala S, Koskinen P (2015) Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyte-macrophage function in vitro. Transpl Immunol 32:175–178
22. Ikezumi Y, Kawachi H, Toyabe S, Uchiyama M, Shimizu F (2000) An anti-CD5 monoclonal antibody ameliorates proteinuria and glomerular lesions in rat mesangioproliferative glomerulonephritis. Kidney Int 58(1):100–114
23. Tomita M, Sogabe H, Nakazato S, Nakatsuji S, Noto T, Hamada K et al (2005) Monoclonal antibody 1-22-3-induced glomerulonephritis in uninephrectomized rats as a model of progressive renal failure. Nephrol Dial Transplant 20(11):2358–2367